Is Cyclacel Pharmaceuticals, Inc. (CYCC) a Buy, Sell, or Hold?
Cyclacel Pharmaceuticals, Inc.
NASDAQ:CYCC
$6.365 USD
-$0.41 (-5.98%)
- Volume
- 219.91K
- Average Volume
- 1.81M
- Market Capitalization
- $10.61M
- P/E Ratio
- -26.54
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $597.60
- Year Low
- $3.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $-0.03
- Current Ratio
- $7.06
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sing Ee Wong |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CYCC |
| CUSIP | 23254L876 |
| CIK | 0001130166 |
| Web | https://www.cyclacel.com |
| Phone | 908 517 7330 |
| Currency | USD |
| Employees | 12 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | -0.03 |
| Current Ratio | 7.06 |
| Quick Ratio | 5.87 |
| Cash Ratio | 4.19 |
Sales & Book Value
| Annual Sales | $747K |
| Price / Sales | 6.96 |
| Cash Flow | -0.92 |
| Price / Cash Flow | -2.10 |
| Price / Book | 5.14 |
Price Target and Rating
| Average Stock Price Forecast | $1.00 |
| High Stock Price Forecast | $1.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | 536.50% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.45 |
| Trailing P/E Ratio | -26.54 |
| PEG Ratio | -0.16 |
| P/E Growth | -0.16 |
| Net Income | $-3M |
| Net Margin | -204.20% |
| Pretax Margin | -202.69% |
| Return on Equity | -72.25% |
| Return on Assets | -41.17% |
Financials Score
| AltmanZ Score | -75.94 |
| Piotroski Score | 3.00 |
| Working Capital | 4.83M |
| Total Assets | 7.56M |
| Ebit | -1.56M |
| Market Cap | 10.61M |
| Total Liabilities | 804K |
Poll Results
About Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Stock
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a ... prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel has collaborated with the University of Texas MD Anderson Cancer Center. This partnership aims to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients with a range of blood cancers, such as chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other forms of advanced leukemia. The company's main operational base is situated in Berkeley Heights, New Jersey.
Frequently Asked Questions
-
What is the current Cyclacel Pharmaceuticals, Inc. (CYCC) stock price?
-
Cyclacel Pharmaceuticals, Inc.(NASDAQ:CYCC) stock price is $6.365 in the last trading session. During the trading session, CYCC stock reached the peak price of $597.59973 while $3.0801 was the lowest point it dropped to. The percentage change in CYCC stock occurred in the recent session was --5.98% while the dollar amount for the price change in CYCC stock was -$-0.41.
-
CYCC's industry and sector of operation?
-
The NASDAQ listed CYCC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYCC?
-
Brian Schwartz | Chief Medical Officer
Sing Ee Wong | Chairman, Chief Executive Officer & President
Grace Kim | Investor Relations Executive
Spiro George Rombotis | President
Gill Christie | Director of Human Resources -
How many employees does CYCC have?
-
Number of CYCC employees currently stands at 12. CYCC operates from 200 Connell Drive, Berkeley Heights, NJ 07922, US.
-
Link for CYCC official website?
-
Official Website of CYCC is: https://www.cyclacel.com
-
How do I contact CYCC?
-
CYCC could be contacted at phone #908 517 7330 and can also be accessed through its website. CYCC operates from 200 Connell Drive, Berkeley Heights, NJ 07922, US.
-
How many shares of CYCC are traded daily?
-
The average number of CYCC shares traded daily for last 3 months was 1.81M.
-
What is the market cap of CYCC currently?
-
The market value of CYCC currently stands at $10.61M with its latest stock price at $6.365